Neuroblastoma Market Research Report Information By Diagnosis (MIBG Scan, Imaging, and Biopsy), By Treatment (Medications, Surgery, Chemotherapy, Radiation Therapy, Stem Cell Transplant, Immunotherapy, and Monoclonal Antibody Treatment), By End User (Hospitals and Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Research Centers, and Others), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) – Market Forecast Till 2032

Global Neuroblastoma Market Overview

Neuroblastoma Market Size was valued at USD 0.35 Billion in 2022. The Neuroblastoma market Diagnosis is projected to grow from USD 0.36 Billion in 2023 to USD 0.47 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.40% during the forecast period (2024 - 2032). increasing government funding in R&D programmes and increasing R&D spending to develop more effective pharmaceuticals, are the key market drivers enhancing the market growth.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Neuroblastoma Market Trends

• Increase in R&D spending to create more effective medications is driving the market growth

Increased R&D spending to provide more effective medications is what is driving the growth of the neuroblastoma industry. Additionally, prominent companies investing heavily in R&D and an increase in neuroblastoma prevalence are propelling market revenue growth. Every year, there are close to 500 new cases of neuroblastoma reported, with the disease's incidence rate being 10.2 instances per million children under the age of 15. This contributes to genetic abnormalities in children's neuroblasts under the age of 15, and occasionally even before the birth of the kid. It is projected that the market for neuroblastoma would expand as a result of the government increasing financing and support for this disease and approving new therapies for it.

The burden of paediatric neuroblastoma is expected to increase in the coming years, and there will also be an increase in research and development for paediatric neuroblastoma treatments. Leukaemias are the most prevalent forms of cancer in children (ages 0 to 14), followed by brain and other CNS tumours, lymphomas, neuroblastoma, kidney tumours, and malignant bone tumours, according to a National Cancer Institute (NCI) November 2021 update. According to the same source, 15,590 kids and teenagers between the ages of 0 and 19 were predicted to receive a cancer diagnosis in 2021.

Additionally, the public's growing awareness of paediatric neuroblastoma therapy and the government's increased spending in R&D activities to enhance the paediatric medical infrastructure are encouraging market expansion. For instance, in March 2022, the Rally Foundation for Childhood Cancer Research awarded grants totaling USD 3.4 million to Drs. Miller Huang and Satyaki Sengupta to investigate the role of chromosome 17q gain in neuroblastoma and Dr. Muxiang Zhou to discover novel MYCN inhibitors of therapy for paediatric neuroblastoma.

Other factors that could boost the demand for paediatric neuroblastoma treatment in the future include rising investments in the development of  healthcare infrastructure, rising demand for drugs and therapeutics to treat neuroblastoma, and the introduction of government initiatives to raise awareness of neuroblastoma. Through 2033, regulatory agencies are expected to approve a rising number of innovative drugs and treatments, which will boost market growth potential. Thus, driving the Neuroblastoma market revenue.

Neuroblastoma Market Segment Insights

Neuroblastoma Diagnosis Insights

The  Neuroblastoma market segmentation, based on Diagnosis, includes MIBG scan, imaging, and biopsy. Imaging segment dominated the  market in 2022. This is explained by how well neuroblastoma diagnostic tests work.

Neuroblastoma Treatment Insights

The  Neuroblastoma market segmentation, based on Treatment, includes medications, surgery, chemotherapy, radiation therapy, stem cell transplant, immunotherapy, and monoclonal antibody treatment. Chemotherapy segment dominated the  market in 2022. Chemotherapy employs anti-cancer drugs, which are frequently injected into a vein. The drugs circulate throughout the body after entering the bloodstream, where they seek out and kill cancer cells. Therefore, neuroblastoma that has spread to the liver, lungs, lymph nodes, bone marrow, liver, or other organs may be treated with chemotherapy. The increasing growth rate of the segment is primarily attributed to the efficacy of chemotherapeutic drugs in the treatment of neuroblastoma as well as the rising incidence of the disease in the paediatric population.

Neuroblastoma End User Insights

The  Neuroblastoma market segmentation, based on End User, includes hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers, and others. Hospitals and clinics segment dominated the  Neuroblastoma market in 2022. This might be attributable to the fact that hospitals and clinics have been updated to offer the greatest neuroblastoma treatment options available.

Figure 1  Neuroblastoma Market, by End User, 2023 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Neuroblastoma Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Neuroblastoma Market dominated this market in 2022 (45.80%). This increase is attributable to both the surge in technologically advanced medications and the rise of neuroblastoma cases. According to estimates for 2020, the U.S. spent more than USD 190 billion on cancer-related healthcare in 2015, and that figure was expected to reach USD 200 billion by that year. The market is expanding as a result of rising healthcare investments as well as the approval of orphan medications for the treatment of neuroblastoma. The rising number of patients receiving chemotherapy and medication to lessen additional disease problems is expected to drive the market's expansion. Further, the U.S. Neuroblastoma market held the largest market share, and the Canada Neuroblastoma market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  NEUROBLASTOMA MARKET SHARE BY REGION 2023 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Neuroblastoma market accounted for the healthy market share in 2022. The market's expansion can be largely ascribed to the rising incidence of childhood cancer and the rising costs of cancer treatment. Additionally, due to its site-specific activity and lack of cytotoxic effects on the body, the first anti-GD2 medication licenced for the treatment of neuroblastoma is in high demand. Additionally, the region's rising infant population and the creation of cutting-edge, novel medicines for the treatment of neuroblastoma are promoting market expansion. Furthermore, the focus on new tumour targets for the development of cell-mediated immunotherapy cancer medications has been made possible by improved awareness of the diagnosis and treatment of neuroblastoma. These elements are therefore anticipated to fuel the market's expansion during the anticipated period. Further, the German Neuroblastoma market held the largest market share, and the U.K Neuroblastoma market was the fastest growing market in the European region

The Asia Pacific Neuroblastoma market is expected to register significant growth from 2024 to 2032. The market's expansion can be mostly ascribed to an ageing population that is on the rise and inadequate healthcare facilities. Due to the presence of emerging nations that are fueling an increase in the incidence of childhood cancer, the Asia Pacific region is predicted to have the fastest growing market. According to estimates, the incidence of COVID-19 will cause the immune system's ability to combat any disease to decline. The number of old and young patients with neuroblastoma who are unaware of the disease is also projected to increase the market's growth. The growth of the market is anticipated to be boosted by the rising number of cancer research facilities that carry out clinical trials for the development of novel medications to stop the disease's spread.  Moreover, China’s Neuroblastoma market held the largest market share, and the Indian Neuroblastoma market was the fastest growing market in the Asia-Pacific region.

Neuroblastoma Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Neuroblastoma market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Neuroblastoma Industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  Neuroblastoma Industry to benefit clients and increase the market sector. In recent years, the Neuroblastoma Industry has offered some of the most significant advantages to medicine. Major players in the Neuroblastoma market, including Edwards Lifesciences Corporation, JenaValveTechnology, Inc., Cigna, Abbott, JC Medical, Inc., Medtronic, Xeltis, Venus Medtech, St. Jude Medical, and SYMETIS, are attempting to increase market demand by investing in research and development operations.

United Therapeutics Corp. (United Therapeutics) creates and markets cutting-edge pharmaceutical treatments for the treatment of infectious diseases and cardiovascular problems, with a focus on pulmonary arterial hypertension. Prostacyclin analogues such as Remodulin (treprostinil injectable), Tyvaso (treprostinil inhalation solution), and Orenitram (treprostinil) are among the company's offerings. The other drugs include Unituxin (dinutuximab), a monoclonal antibody for oncologic purposes, and Adcirca (tadalafil), a phosphodiesterase type 5 (PDE-5) inhibitor. Monoclonal antibodies (mAbs), glycobiology antiviral drugs, and cell-based therapeutics are some of its product candidates. The business also works on pre-clinical modified lungs for transplantation. In its Silver Spring, Maryland, plant, it produces goods. It sells its goods in Israel, South America, Europe, and the US. United Therapeutics' main office is in Silver Spring, Maryland, in the United States. Unituxin, a medication used to treat paediatric neuroblastoma at high risk, was approved by Health Canada in November 2018 by United Therapeutics Corporation.

A biotechnology business at the clinical stage is Provectus Biopharmaceuticals, Inc. The Company's primary objective is the development of halogenated xanthenes (HXs), a type of synthetic small-molecule immuno-catalysts, as immunotherapy drugs for a variety of disorders. The lead molecule for the company is known as rose bengal sodium (RBS). The Company's small molecule HX medical science platform includes a variety of various therapeutic product candidates and preclinical pharmaceutical-grade RBS formulations that are tailored to each disease area and/or indication. These formulations use varying doses and delivery methods. The HX medical science platform of the company consists of in vitro drug discovery programmes for infectious diseases and tissue regeneration and repair, as well as clinical development programmes in oncology, dermatology, and ophthalmology. It also includes in vivo proof-of-concept drug discovery programmes for oncology, haematology, wound healing, and animal health. For the treatment of paediatric neuroblastoma, PROVECTUS BIOPHARMACEUTICALS, INC.'s PV-10 small molecule oncolytic immunotherapy received FDA approval in November 2018.

Key Companies in the Neuroblastoma market include

• Lonza Biologics Ltd 


• PerkinElmer Inc.


• BD Biosciences


• bioMerieux


• Beckman Coulter Inc.


• GE healthcare


• EMD Chemicals Inc. 


• Meridian Life science Inc.


• Shimadzu Biotech


• Takara Bio Inc.

Neuroblastoma Industry Developments

Oct 2019 A clinical update on naxitamab for the treatment of neuroblastoma and osteosarcoma was released by Y-mAbs Therapeutics, Inc. during the International Society of Paediatric Oncology (SIOP) Annual Congress in Lyon, France.

October 2022 The clinical trial was sponsored by Kyushu University and was titled "Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas or Malignant Paediatric Solid Tumours With Lung Metastases" in order to assess the safety of GAIA-102 alone in refractory/relapse neuroblastoma or paediatric solid tumours with lung metastases and determine a recommended dose for Phase II.

Neuroblastoma Market Segmentation

Neuroblastoma Diagnosis Outlook

• MIBG Scan


• Imaging


• Biopsy

Neuroblastoma Treatment Outlook

• Medications


• Surgery


• Chemotherapy


• Radiation Therapy


• Stem Cell Transplant


• Immunotherapy


• Monoclonal Antibody Treatment

Neuroblastoma End User Outlook

• Hospitals and Clinics


• Ambulatory Surgical Centers


• Diagnostic Centers


• Research Centers


• Others

Neuroblastoma Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America